Nuevocor
Nuevocor is a Singapore-headquartered biotechnology company focused on developing treatments for cardiomyopathies caused by aberrant mechanobiology. The company is advancing its lead candidate, NVC-001, targeting LMNA-related dilated cardiomyopathy, through Phase 1/2 clinical trials to establish clinical proof-of-concept.
Leadership & Board
- Current Number of Employees
- 29
- Current LinkedIn Followers
- 3,127
Latest Estimated Valuation
- Estimated Valuation
- ―
- Total Amount Raised
- $45M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $45M
- Latest Funding Round
- Series B
- Post-Money Valuation
- ―
Company Momentum Positive
Nuevocor LinkedIn following is increasing, signaling rising market interest, while its workforce is growing, indicating business expansion.
Employee Trend
Nuevocor had 29 employees as of October 12, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
Nuevocor had 3,127 followers as of October 12, 2026. The number of followers increased by 49 (1.59%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| May 06, 2025 | Series B | $45.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Boehringer Ingelheim Venture Fund | Series B |
| ClavystBio | Series B |
| SEEDS Capital | Series B |
| EDBI | Series B |
| Kurma Partners | Series B |
| Angelini Ventures | Series B |
| Highlight Capital | Series B |
Similar Companies
A snapshot of private companies similar to Nuevocor, helping you discover and navigate related company profiles.
Related News and Analysis
